ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TEMPORARY UNAVAILABILITY OF NATESTO® IN CANADA AND SOUTH KOREA
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 196271" data-attributes="member: 13851"><p>[URL unfurl="true"]https://thecbq.ca/acerus-pharmaceuticals-tsx-asp-otcqb-aspcf-president-ceo-ed-gudaitis-building-a-sustainable-value-driven-company/[/URL]</p><p></p><p><strong>A TSX-listed commercial-stage pharmaceutical company, Acerus Pharmaceuticals has the vision to become a leading specialty pharmaceutical company focused on urology and Men’s Health with its nasal testosterone treatment, Natesto.</strong></p><p></p><p><em>Founded in 2009 and listed on the TSX (ASP) and the OTCQB (ASPCF), Acerus Pharmaceuticals is a micro-cap with a market cap of $50m CAD as of August 25th, 2020. Company President and CEO Ed Gudaitis has held numerous senior positions in multinational pharmaceutical companies, working in both Canada and the United States, and has been responsible throughout his career for launching and building billion-dollar pharmaceutical product franchises and country operations. Mr. Gudaitis discusses Natesto, the firm’s disruptive technology that can potentially secure a significant share in a more than $1 billion USD global market, the unique opportunity available to potential investors in the company, and Acerus’ vision to become a leading specialty pharmaceutical company in urology and Men’s Health.</em></p><p></p><p></p><p><strong>Nasal testosterone</strong></p><p></p><p><em>“Acerus is a commercial-stage specialty pharmaceutical company,” Mr. Gudaitis explains. “We have an approved product on the market that we are commercializing, and our focus of the effort is on specialists, not primary care physicians.”</em></p><p><em></em></p><p><em><strong>Although the company is based in Ontario, Canada, its business is global. The company manufactures and commercializes its core product, Natesto, in a number of global markets, including the US, Canada, South Korea, and Taiwan, with plans to move into Europe in the next eighteen months.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>“In the US and Canada we commercialize the product directly through our own sales and marketing efforts, while in South Korea and Taiwan, and eventually in Europe, we commercialize through partnerships with local operating companies.”</strong></em></p><p><em></em></p><p><em>Unlike some other companies in the specialty pharma space, Acerus is not built on licensing in other people’s assets. Acerus’ focus is on manufacturing and commercializing its core product in-house, making it a unique proposition as a company.</em></p><p><em></em></p><p><em>“We’ve been around for a while. Formed in 2009, the company has gone through a couple of iterations of strategy. It was previously called the Trimel Pharmaceuticals company, and it was structured to capitalize on core technology, our nasal gel technology, which enables us to deliver products in a unique, patient-friendly manner.”</em></p><p><em></em></p><p><em><strong>The problem that the company looks to solve is very unique. Our primary market opportunity is the treatment of low testosterone, otherwise known as male hypogonadism. Around 14 million US males potentially have low testosterone, making a sizeable possible market.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>“It’s about a $1bn USD prescription product market opportunity in the United States, with about 7 million prescriptions written per year. There are products that exist today, however, there is no truly ideal product in the marketplace. There are a number of products with challenges in terms of how they’re delivered.”</strong></em></p><p><em></em></p><p><em>The main options in the market for low testosterone currently are testosterone injections, deep and painful injections with a large needle, presenting challenges with self-injection. There are also topical gels, which act like a skin lotion that you rub in each day.</em></p><p><em></em></p><p><em>“With the topical gels, you have to worry about potentially transferring the product to your spouse or your children,” Mr. Gudaitis explains. “After you apply the product to your body, you have to let it dry for twenty minutes, it can absorb differentially and not evenly all the time. As a result, there are several challenges with existing products in this market.”</em></p><p><em></em></p><p><em>It is estimated that up to 70% of patients on prescription treatments for low testosterone will switch therapy at least once to look for better options, as patients and their physicians are unsatisfied with the current treatments available.</em></p><p><em></em></p><p><em>“Prescription treatment of low testosterone is a very large market that has been well established. Physicians know how to diagnose, treat and prescribe low testosterone treatments. However, there is no single ideal product in the market. We think we can solve a number of problems within this large market, providing a patient-friendly, safer, effective alternative in a very large and growing market opportunity.”</em></p><p><em></em></p><p><em><strong>Acerus’ unique technology creates a different product than any other in the market for testosterone treatment, <u>an intra-nasal gel application of testosterone applied with a small dispenser three times a day on the inside of your nostril</u>.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>“It’s a little bit like a topical hand lotion that you would put on your hand. <u>It’s a gel, not a spray, applied with our dispenser on the inside of your nasal cavity</u>. <u>The product is rapidly absorbed, highly effective, with low side effects</u>.”</strong></em></p><p></p><p>[ATTACH=full]13017[/ATTACH]</p><p></p><p></p><p><strong>Unsatisfied market</strong></p><p></p><p><em>The uniqueness of this nasal testosterone technology offers investors an exciting opportunity to invest in a company with a highly differentiated, unique product offering. The technology is an Acerus propriety technology, which was licensed by Acerus, protected by a strong patent strategy.</em></p><p><em></em></p><p><em><strong><em>“The Intellectual Property in the US, Canada, and Europe are very long-ranging. <u>We have a current suite of patents that would take us into the mid-2020s</u>. <u>We have new patent filings and strategies that we’re actively working on that would take patent protection into the early and potentially the late-2030s</u>. We have unique technology and a solid IP platform to work from.”</em></strong></em></p><p><em></em></p><p><strong><em>This means the company has a ten or twelve-year run in front of it with a very large, unsatisfied market opportunity to be capitalized on. <u>This opportunity is primarily in the United States, but there is also significant market opportunity in the Canadian and European markets</u>.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 196271, member: 13851"] [URL unfurl="true"]https://thecbq.ca/acerus-pharmaceuticals-tsx-asp-otcqb-aspcf-president-ceo-ed-gudaitis-building-a-sustainable-value-driven-company/[/URL] [B]A TSX-listed commercial-stage pharmaceutical company, Acerus Pharmaceuticals has the vision to become a leading specialty pharmaceutical company focused on urology and Men’s Health with its nasal testosterone treatment, Natesto.[/B] [I]Founded in 2009 and listed on the TSX (ASP) and the OTCQB (ASPCF), Acerus Pharmaceuticals is a micro-cap with a market cap of $50m CAD as of August 25th, 2020. Company President and CEO Ed Gudaitis has held numerous senior positions in multinational pharmaceutical companies, working in both Canada and the United States, and has been responsible throughout his career for launching and building billion-dollar pharmaceutical product franchises and country operations. Mr. Gudaitis discusses Natesto, the firm’s disruptive technology that can potentially secure a significant share in a more than $1 billion USD global market, the unique opportunity available to potential investors in the company, and Acerus’ vision to become a leading specialty pharmaceutical company in urology and Men’s Health.[/I] [B]Nasal testosterone[/B] [I]“Acerus is a commercial-stage specialty pharmaceutical company,” Mr. Gudaitis explains. “We have an approved product on the market that we are commercializing, and our focus of the effort is on specialists, not primary care physicians.” [B]Although the company is based in Ontario, Canada, its business is global. The company manufactures and commercializes its core product, Natesto, in a number of global markets, including the US, Canada, South Korea, and Taiwan, with plans to move into Europe in the next eighteen months. “In the US and Canada we commercialize the product directly through our own sales and marketing efforts, while in South Korea and Taiwan, and eventually in Europe, we commercialize through partnerships with local operating companies.”[/B] Unlike some other companies in the specialty pharma space, Acerus is not built on licensing in other people’s assets. Acerus’ focus is on manufacturing and commercializing its core product in-house, making it a unique proposition as a company. “We’ve been around for a while. Formed in 2009, the company has gone through a couple of iterations of strategy. It was previously called the Trimel Pharmaceuticals company, and it was structured to capitalize on core technology, our nasal gel technology, which enables us to deliver products in a unique, patient-friendly manner.” [B]The problem that the company looks to solve is very unique. Our primary market opportunity is the treatment of low testosterone, otherwise known as male hypogonadism. Around 14 million US males potentially have low testosterone, making a sizeable possible market. “It’s about a $1bn USD prescription product market opportunity in the United States, with about 7 million prescriptions written per year. There are products that exist today, however, there is no truly ideal product in the marketplace. There are a number of products with challenges in terms of how they’re delivered.”[/B] The main options in the market for low testosterone currently are testosterone injections, deep and painful injections with a large needle, presenting challenges with self-injection. There are also topical gels, which act like a skin lotion that you rub in each day. “With the topical gels, you have to worry about potentially transferring the product to your spouse or your children,” Mr. Gudaitis explains. “After you apply the product to your body, you have to let it dry for twenty minutes, it can absorb differentially and not evenly all the time. As a result, there are several challenges with existing products in this market.” It is estimated that up to 70% of patients on prescription treatments for low testosterone will switch therapy at least once to look for better options, as patients and their physicians are unsatisfied with the current treatments available. “Prescription treatment of low testosterone is a very large market that has been well established. Physicians know how to diagnose, treat and prescribe low testosterone treatments. However, there is no single ideal product in the market. We think we can solve a number of problems within this large market, providing a patient-friendly, safer, effective alternative in a very large and growing market opportunity.” [B]Acerus’ unique technology creates a different product than any other in the market for testosterone treatment, [U]an intra-nasal gel application of testosterone applied with a small dispenser three times a day on the inside of your nostril[/U]. “It’s a little bit like a topical hand lotion that you would put on your hand. [U]It’s a gel, not a spray, applied with our dispenser on the inside of your nasal cavity[/U]. [U]The product is rapidly absorbed, highly effective, with low side effects[/U].”[/B][/I] [ATTACH type="full" alt="Screenshot (3584).png"]13017[/ATTACH] [B]Unsatisfied market[/B] [I]The uniqueness of this nasal testosterone technology offers investors an exciting opportunity to invest in a company with a highly differentiated, unique product offering. The technology is an Acerus propriety technology, which was licensed by Acerus, protected by a strong patent strategy. [B][I]“The Intellectual Property in the US, Canada, and Europe are very long-ranging. [U]We have a current suite of patents that would take us into the mid-2020s[/U]. [U]We have new patent filings and strategies that we’re actively working on that would take patent protection into the early and potentially the late-2030s[/U]. We have unique technology and a solid IP platform to work from.”[/I][/B] [/I] [B][I]This means the company has a ten or twelve-year run in front of it with a very large, unsatisfied market opportunity to be capitalized on. [U]This opportunity is primarily in the United States, but there is also significant market opportunity in the Canadian and European markets[/U].[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TEMPORARY UNAVAILABILITY OF NATESTO® IN CANADA AND SOUTH KOREA
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top